Han HH - Search Results

1

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents.

Lopez P, Bravo L, Buntinx E, Borja-Tabora C, Velasquez H, Rodriquez EJ, Rodriguez CA, Carlos J, Montellano MEB, Alberto ER, Salvani-Bautista M, Huang Y, Hu B, Li P, Han HH, Baccarini C, Smolenov I. Lopez P, et al. Among authors: han hh. Hum Vaccin Immunother. 2023 Dec 31;19(1):2206359. doi: 10.1080/21645515.2023.2206359. Epub 2023 May 25. Hum Vaccin Immunother. 2023. PMID: 37226504 Free PMC article. Clinical Trial.

2

A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth.

Gatchalian S, Reyes M, Bernal N, Lefevre I, David MP, Han HH, Bock HL, Wolter J, Schuerman L. Gatchalian S, et al. Among authors: han hh. Hum Vaccin. 2005 Sep-Oct;1(5):198-203. doi: 10.4161/hv.1.5.2163. Epub 2005 Sep 7. Hum Vaccin. 2005. PMID: 17012860 Clinical Trial.

3

A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life.

Gatchalian S, Reyes M, Bermal N, Chandrasekaran V, Han HH, Bock HL, Lefevre I. Gatchalian S, et al. Among authors: han hh. Hum Vaccin. 2008 Jan-Feb;4(1):60-6. doi: 10.4161/hv.4.1.5069. Epub 2007 Sep 23. Hum Vaccin. 2008. PMID: 18376148

4

Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants.

Vesikari T, Karvonen A, Bouckenooghe A, Suryakiran PV, Smolenov I, Han HH. Vesikari T, et al. Among authors: han hh. Vaccine. 2011 Mar 3;29(11):2079-84. doi: 10.1016/j.vaccine.2011.01.004. Epub 2011 Jan 14. Vaccine. 2011. PMID: 21238572 Clinical Trial.

5

Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life.

Kawamura N, Tokoeda Y, Oshima M, Okahata H, Tsutsumi H, Van Doorn LJ, Muto H, Smolenov I, Suryakiran PV, Han HH. Kawamura N, et al. Among authors: han hh. Vaccine. 2011 Aug 26;29(37):6335-41. doi: 10.1016/j.vaccine.2011.05.017. Epub 2011 Jun 2. Vaccine. 2011. PMID: 21640780 Clinical Trial.

6

Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.

Omenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, Smolenov IV, Han HH; ROTA-054 Study Group. Omenaca F, et al. Among authors: han hh. Pediatr Infect Dis J. 2012 May;31(5):487-93. doi: 10.1097/INF.0b013e3182490a2c. Pediatr Infect Dis J. 2012. PMID: 22228231 Clinical Trial.

7

Evaluation of a new syringe presentation of reduced-antigen content diphtheria, tetanus, and acellular pertussis vaccine in healthy adolescents--A single blind randomized trial.

Pavia-Ruz N, Abarca K, Lepetic A, Cervantes-Apolinar MY, Hardt K, Jayadeva G, Kuriyakose S, Han HH, de la O M. Pavia-Ruz N, et al. Among authors: han hh. Hum Vaccin Immunother. 2015;11(7):1770-4. doi: 10.1080/21645515.2015.1041697. Hum Vaccin Immunother. 2015. PMID: 26075317 Free PMC article. Clinical Trial.

8

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.

Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, Li P, Liang P, Han HH, Liang J, Clemens R. Richmond P, et al. Among authors: han hh. Lancet. 2021 Feb 20;397(10275):682-694. doi: 10.1016/S0140-6736(21)00241-5. Epub 2021 Jan 29. Lancet. 2021. PMID: 33524311 Free PMC article. Clinical Trial.

9

Persistence of the Immune Responses and Cross-Neutralizing Activity With Variants of Concern Following 2 Doses of Adjuvanted SCB-2019 Coronavirus Disease 2019 Vaccine.

Richmond PC, Hatchuel L, Pacciarini F, Hu B, Smolenov I, Li P, Liang P, Han HH, Liang J, Clemens R. Richmond PC, et al. Among authors: han hh. J Infect Dis. 2021 Nov 22;224(10):1699-1706. doi: 10.1093/infdis/jiab447. J Infect Dis. 2021. PMID: 34480575 Free PMC article. Clinical Trial.

10

Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines.

Ambrosino D, Han HH, Hu B, Liang J, Clemens R, Johnson M, Siber G, Goldblatt D. Ambrosino D, et al. Among authors: han hh. J Infect Dis. 2022 Jan 18;225(2):327-331. doi: 10.1093/infdis/jiab574. J Infect Dis. 2022. PMID: 34888662 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

301 results

Search Page